A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
Study sponsor: Agios Pharmaceuticals, Inc. · AGIO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-13Actual
Enrollment · participants30Actual
Source updated2026-10-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.